Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.70 |
| ▸ | NT5E | P21589 | 4/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069338 | 1.00 | ADORA3 (0.70) | ADORA3NT5EADORA1ADORA2AADORA2B | |
| SCHEMBL6659384 | 0.88 | ADORA3 (0.75) | ADORA3NT5EADORA1ADORA2AADORA2B | |
| SCHEMBL6659397 | 0.88 | ADORA3 (0.75) | ADORA3NT5EADORA1ADORA2AADORA2B | |
| SCHEMBL7067730 | 0.87 | ADORA1 (0.77) | ADORA3ADORA1ADORA2AADORA2BRXFP1 | |
| SCHEMBL7067723 | 0.87 | ADORA1 (0.77) | ADORA3ADORA1ADORA2AADORA2BRXFP1 | |
| SCHEMBL7734131 | 0.86 | ADORA3 (0.53) | ADORA3NT5EADORA1ADORA2AADORA2B | |
| SCHEMBL6574678 | 0.85 | ADORA3 (0.89) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL6574672 | 0.85 | ADORA3 (0.89) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL31088644 | 0.82 | NT5E (1.00) | ADORA3NT5EADORA1ADORA2AADORA2B | |
| SCHEMBL22206560 | 0.82 | NT5E (1.00) | ADORA3NT5EADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027363-B1 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2003-06-04 | — | — | EP | claimed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | claimed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | claimed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |